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1. INTRODUCTION 
Fibronectin (FN) is a multifunctional glycopro- 
tein present in the soluble form in plasma and 
other body fluids and in the insoluble form in the 
extracellular matrices and basement membranes. 
The functions attributed to fibronectin such as 
cell-cell and cell-substrate adhesion, cell spreading, 
enhancement of phagocytosis, cell migration, 
wound healing and ability to induce a more normal 
phenotype in transformed cells seem to be all based 
on its affinity to cell surfaces and to many dif- 
ferent macromolecules including collagens, fibrin, 
fibrinogen, heparin, DNA, actin, complement 
component Clq and gangliosides (for reviews on 
distribution, structure and biological functions of 
fibronectin see [l-7]). 
molecule varies from an almost extended confor- 
mation to a compact form depending on solvent 
conditions. Recent studies on purified fibronectin 
suggested a rather compact conformation under 
near physiological conditions and a more 
elongated structure at high ionic strength, pH or 
glycerol content [ 13-171. Since all the studies on 
fibronectin conformation have been done on 
purified fibronectin we have investigated with the 
aid of immunological procedures the hydrodyna- 
mic properties of fibronectin in whole plasma. 
These data indicate that fibronectin is present in 
plasma in a compact conformation. 
2. MATERIALS AND METHODS 
The human plasma fibronectin molecule is com- 
posed of two polypeptides (cu and p chains) with a 
relative molecular mass of about 220 kDa. These 
subunits may have slight differences in sequence 
and are linked as a dimer via interchain disulfide 
bonds near the C-terminus. These subunits are 
chains of independent globular domains connected 
by short flexible segments of polypeptide chain. 
The length of a fibronectin subunit is about 70 nm 
and its width 2 nm. Physicochemical and electron 
microscopy studies [S- 121 on purified fibronectin 
indicate that the shape of the purified fibronectin 
Human plasma fibronectin and monospecific 
antibodies to fibronectin were prepared as in [ 181. 
Diffusion coefficient (Dzo,~) and molecular exclu- 
sion chromatography measurements were both 
carried out at two different NaCl concentrations, 
137 and 600 mM, in 8 mM Na-phosphate buffer 
(pH 7.2), 2.7 mM KCl, 1 mM NazEDTA, 10 
units/ml kallidogenase inhibitor (KIR, Richter, 
Milan), 0.02% (w/v) NaNs. All samples were ex- 
tensively dialyzed against’the buffer in which the 
measurements were to be done. Diffusion coeffi- 
cient measurements in 0.8% agarose plates were 
carried out as in [19]. Stokes’ radii (R,) were 
calculated from the Dzo,~ as in [20]. 
* TO whom reprint requests should be addressed Molecular exclusion chromatography was car- 
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ried out on a column of 2.6 cm diameter filled with 
Ultrogel AcA-22 (LKB, Bromma, Sweden) to a 
bed height of 91.6 cm, for a total volume (V,) of 
486 ml. Flow rate was 10 ml/h with upward elu- 
tion. Elution volumes (V,) of purified proteins 
were determined by continuous monitoring of the 
eluate’s absorbance at 280 nm. When whole 
plasma was analyzed, fractions were collected and 
analyzed using the fused rocket immunoelec- 
trophoresis technique [21] with antibodies specific 
to IgM, a*-macroglobulin (Behring, Marburg) and 
fibronectin. The column was calibrated by deter- 
mining the elution volumes of 5 proteins of known 
R,: human IgM, R, = 12.5 nm, human 
a2-macroglobulin (cuz-M), R, = 9.3 nm, bovine 
thyroglobulin, R, = 8.5 nm, horse ferritin, R, = 
6.1 nm, and bovine catalase, R, = 5.22 nm. The 
elution volumes of the first two proteins were 
measured directly from experiments with whole 
human plasma. The last 3 proteins were part of a 
commercial high-Mr calibration kit (HMV Calibra- 
tion Kit, Pharmacia, Uppsala) as well as the Blue 
Dextran 2000 (i%G 2 x 106) that was used for the 
column void volume ( VO) determination. A plot of 
iz (Kav = (I’, - I’,)/ v, - I’,) [221) vs R, 
was linear from the bovine catalase value to the 
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human ~YZ-M value while the human IgM value fell 
in the non-linear portion of the curve. Since 
molecular asymmetry can strongly affect the elu- 
tion behaviour of a macromolecule [23], the R, 
values calculated this way have been taken as ‘ap- 
parent R,' (R,(app)). All measurements have been 
carried out at room temperature. 
3. RESULTS 
We have studied the elution behaviour of 
fibronectin either purified or in whole plasma from 
a molecular exclusion chromatography column 
(Ultrogel AcA-22) at two different NaCl concen- 
trations (137 and 600 mM). The elution profile of 
fibronectin in whole plasma was obtained using 
fused rocket immunoelectrophoresis. To obtain 
the relative elution position of fibronectin with 
respect to other proteins we used an intermediate 
gel containing antibodies to IgM and &Z-M. Fig. 1A 
and B shows the elution profiles of total human 
plasma protein from the Ultrogel AcA-22 
molecular exclusion chromatography column. The 
insets show the immunochemical elution profile of 
IgM, CY~-M and fibronectin. In table 1 are sum- 
marized the elution volumes and the calculated 
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Fig.1. Elution profiles of total plasma proteins from the Ultrogel AcA-22 column. Conditions as in section 2. (A) In 
137 mM NaCl, 2.9 ml/fraction; the peaks in the immunochemical elution profile in the inset are, from left to right, 
IgM, a~-M and FN. (B) In 600 mM NaCl, 2.86 ml/fraction; the peaks in the immunochemical elution profile in the 
inset are, from left to right, IgM, FN and (YZ-M. 
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Elution volumes and apparent Stokes’ radii from molecular exclusion chromatography 
Sample [NaCI] 
137 mM 600mM 
V, (ml) Wapp) V, (ml) K(app) 
(nm) (nm) 
FN, purified 275.5 + 2a 8.4 246 z+ 2a 10.1 
FN, whole plasma 276 * O.Sb 8.4 245 + 2b 10.2 
~z-M, whole plasma 262 + OSb 9.1 259 + 2b 9.3 
IgM, whole plasma 236 f 3b 10.9 229 f 3b 11.3 
Blue Dextran 2000 183 - 181 - 
a Mean of 3 expts + SD 
b Mean of 2 expts + mean deviation 
R,(app), at the two different NaCl concentrations, 
of fibronectin (purified and in whole plasma), 
IgM, and a~-M. 
The back-calculated R,(app) value for 02-M is in 
agreement with the literature, while the IgM value 
is considerably lower. Here we have assumed, in 
the absence of a suitable standard, that the linear 
portion of the calibration curve extends a little 
over the a~-M value to include the FN value at high 
ionic strength. While (YZ-M and IgM at the two dif- 
ferent NaCl concentrations do not show significant 
variations in their elution volumes, the Ve of FN, 
both purified and in whole plasma, shows a dif- 
ference of about 30 ml, corresponding to a signifi- 
cant change in the R,(app) value. 
A . . f3 
Fig.2. Diffusion coefficient measurements in 0.8% 
agarose plates. x-axis troughs, anti-human plasma FN 
monospecific antibodies; y-axis troughs, whole human 
plasma. Conditions as in section 2, with 0.1% (w/v) 
NaNs. The angle between the antigen (FN)-antibody 
(IgG) precipitation line and the antigen trough was 
measured with a protractor. (A) 137 mM NaCI. (B) 
600 mM NaCl. 
Table 2 
Fibronectin diffusion coefficients and Stokes’ radii from 
immunodiffusion experiments with whole human 
plasma 
[NaCl] 
@Ml 
Angle D2o.w x lo7 R, (nm) 
(cm2/s) 
137 36 50’ + 50’” 2.20 + O.lOa 9.1 f 0.4a 
600 33 50’ * 14’b 1.78 * O.OSb 12.0 f 0.3b 
a Mean of 3 expts + SD 
b Mean of 4 expts * SD 
We have also measured the diffusion coeffi- 
cients of FN in whole plasma at the two different 
NaCl concentrations using the agarose plates as 
cited in section 2. Typical experiments are shown 
in fig.2, and the results are summarized in table 2, 
which also contains the calculated R,. Again, we 
have observed a significant increase in the FN R, 
value from near-physiological conditions to high 
ionic strength. 
4. DISCUSSION 
Reversible variation of purified fibronectin from 
a compact to an extended form induced by chang- 
ing solvent composition has been observed in elec- 
tron microscopy and physicochemical studies 
[ 12-171. An extended conformation has been 
observed at high pH, at high ionic strength, in 30% 
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glycerol and in 1 M urea. However, the conforma- 
tional state of native fibronectin circulating in 
plasma, free to interact with other plasma pro- 
teins, is unknown, 
Here we have studied the diffusion coefficient, 
using agarose plates, and the elution from a 
molecular exclusion chromatography column of 
human plasma fibronectin in whole plasma at two 
different NaCl concentrations. The R, calculated 
from the diffusion coefficients are in agreement 
with those reported in the literature for purified 
fibronectin under similar solvent conditions. The 
R,(app) values obtained by molecular exclusion 
chromatography differ from that obtained by 
coefficients by about 15%. This may be due to the 
different sensitivity of the two methods to 
molecular asymmetry. These data indicate that at 
physiological NaCl concentration, FN is present in 
whole plasma with a compact form susceptible to 
change into a more open one at higher [NaCl] as 
previously demonstrated using purified FN. 
Although the conformational change of fibronec- 
tin from the compact to the open form has been 
suggested as a means of unmasking previously hid- 
den active sites, it is not known if in vivo there are 
physiological conformational transitions. Further 
studies are needed to establish the biological 
significance of the different fibronectin conforma- 
tional states and the possible mechanism triggering 
these conformational changes in vivo. 
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